Treatment of diffuse large cell non-Hodgkin’s lymphomas

  • R. I. Fisher
  • V. T. DevitaJr.
  • D. L. Longo
  • D. C. Ihde
  • R. C. Young
Part of the Developments in Oncology book series (DION, volume 32)

Abstract

Advanced stages of diffuse mixed lymphoma, diffuse histiocytic or large cell lymphoma, and diffuse undifferentiated non-Burkitt’s lymphoma have traditionally been considered rapidly progressive, fatal diseases. During the 1960s, few of these patients survived for five years [1]. In 1975, it became apparent that combination chemotherapy could achieve long-term disease-free survival in advanced diffuse histiocytic lymphoma [2]. This observation was confirmed soon thereafter [3–6] and, by 1977, it was established that complete remissions, documented by re-evaluation of all initially involved sites, could be obtained in approximately 40–50% of these patients, and that 75–80% of the complete responders would have long-term disease-free survival. In 1983, results of the ProMACE-MOPP treatment program suggested further improvement in these therapeutic results [7]. Several other studies also indicated significantly prolonged survival [8–10]. At present, long-term disease-free survival may be achieved in approximately 60% of all patients with advanced stages of diffuse aggressive lymphomas.

Keywords

Toxicity Lymphoma Pneumonia Stratification Doxorubicin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jones SE, Rosenberg SA, Kaplan HS et al. (1972). Non-Hodgkin’s lymphomas. II. Single agent chemotherapy. Cancer 30: 31–38.PubMedCrossRefGoogle Scholar
  2. 2.
    DeVita VT, Canellos GP, Chabner BA et al. (1975). Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1: 248–250.PubMedCrossRefGoogle Scholar
  3. 3.
    Berd D, Cornog J, DeConti R et al. (1975). Long term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy. Cancer 35: 1050–1054.PubMedCrossRefGoogle Scholar
  4. 4.
    Jones SE, Grozea PN, Metz EN et al. (1979). Superiority of adriamycin containing combination chemotherapy in the treatment of diffuse lymphoma. Cancer 43: 417–425.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • R. I. Fisher
    • 1
  • V. T. DevitaJr.
    • 1
  • D. L. Longo
    • 1
  • D. C. Ihde
    • 1
  • R. C. Young
    • 1
  1. 1.Medicine Branch and Naval Medical Oncology BranchNational Cancer InstituteBethesdaUSA

Personalised recommendations